The randomized, double-blind study will enroll about 150 patients to receive intravenous ALT001 at one of two doses or placebo, with functional change assessed at 24 weeks.
The UMC Utrecht-sponsored, randomized placebo-controlled study plans to enroll 162 infants with MRI-confirmed hypoxic-ischemic brain injury and assess motor development at 24 months.
The Chinese company also received an IND in China a few weeks ago. Supported by good preclinical data, they'll advance clinical trials in both countries soon.
The Phase II study will test XellSmart’s iPSC-derived off-the-shelf cell therapy in 30 Parkinson’s patients after Phase I showed meaningful motor and quality-of-life gains with no transplant-related adverse events.
Keck Medicine of USC is participating in a small Phase 1 clinical trial evaluating the safety and early effectiveness of implanting induced pluripotent stem cell-derived dopamine-producing cells into the brain for Parkinson’s disease.
Aspen’s trial advances with a commercial-ready, patient-derived cell therapy aiming to improve Parkinson’s outcomes and streamline clinical delivery.
The exPDite-2 trial will evaluate the safety and effectiveness of donor-derived stem cell therapy in Parkinson’s disease patients.
The trial will inject autologous stem cells directly into the brain to bypass the blood-brain-barrier.
A new clinical trial in Texas will evaluate stem cell therapy’s potential to improve outcomes for adults with chronic TBI.
Researchers will test whether nasal drops containing stem cell-derived vesicles can safely benefit people with a range of neurodegenerative diseases.
Hope Biosciences will study whether stem cell therapy can reduce inflammation or slow Alzheimer’s progression in a new clinical trial.
The study will test whether combining umbilical cord stem cells and spinal cord stimulation can safely help people with chronic spinal cord injury.
The Israeli regenerative medicine company is moving one step closer to clinical trials for serious neurological indications such as TBI, spinal cord injury, etc.
BrainStorm's NurOwn, its ALS candidate stem cell therapy, has shown significantly higher five-year survival rates compared to expectations in a small 10 participant program.
The Chinese biotech company reports that the patient showed notable improvements in sleep quality and motor function, with no serious adverse events.
A new milestone for iPSC therapy in the USA, this is one to watch.
The neurorehabilitation hospital in Spain will investigate if allogeneic umbilical-derived stem cell therapy can help enhance recovery.
This study will evaluate if allogeneic human induced pluripotent stem cell (iPSC)-derived motor neuron progenitor cells (XS228, made by XellSmart) can safely and effectively treat subacute spinal cord injury. Researchers at the Third Affiliated Hospital, Sun Yat-Sen University, in collaboration…
Brainstorm Therapeutics is back, and they've learned a lot from their previous trials. If you don't know the history of Nurown, their ALS stem cell candidate, it showed early promise in Phase 2 with some slowed disease progression. In Phase…
Will adipose stem cell therapy hold an answer for neuroinflammation, a factor in Alzheimer's?
This follows their RMAT designation, and promising Phase 1/2 trial results, which they presented earlier this year.